This interview with Dr Monty Pal, Associate Professor from the City of Hope National Medical Center in California, USA discusses tumour shrinkage in patients who did not have a nephrectomy. The interview was conducted at the European Society of Medical Oncology (ESMO) 2019 conference in Barcelona earlier this month.
Dr Pal discusses the results from a subgroup analyses of the data from the JAVELIN Renal 101 trial, which looks at tumour shrinkage in metastatic renal cell carcinoma (RCC) patients who did not undergo cytoreductive nephrectomy.
Consistent with the data from the overarching JAVELIN Renal 101 trial, it demonstrated that axitinib with avelumab did have the ability to shrink primary tumours to a greater extent than sunitinib did. This treatment strategy gives patients with a huge intact primary tumour the option of potentially downsizing tumours to facilitate surgery, particularly for patients who were originally not suitable for a nephrectomy.